Target Name: CDCA3
NCBI ID: G83461
Review Report on CDCA3 Target / Biomarker Content of Review Report on CDCA3 Target / Biomarker
CDCA3
Other Name(s): CDCA3 variant 1 | Cell division cycle-associated protein 3 (isoform 1) | cell division cycle associated 3 | gene-rich cluster protein C8 | CDCA3_HUMAN | GRCC8 | TOME1 | Cell division cycle associated 3, transcript variant X3 | Trigger of mitotic entry 1 | Trigger of mitotic entry protein 1 | TOME-1 | Gene-rich cluster protein C8 | Cell division cycle-associated protein 3 (isoform X4) | trigger of mitotic entry protein 1 | CDCA3 variant X3 | Cell division cycle-associated protein 3 | Cell division cycle associated 3, transcript variant 1

CDCA3: A Potential Drug Target and Biomarker for Multiple Sclerosis

Introduction

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disorder that affects approximately 450,000 people worldwide. The exact cause of MS is still unclear, but research has identified several factors that contribute to its development, including genetic, environmental, and immunological factors. One of the leading theories is the role of inflammation in MS, and the use of disease-modifying therapies (DMTs) has contributed to our understanding of the disease.

CDCA3, a protein that is expressed in the central nervous system (CNS), has been identified as a potential drug target and biomarker for MS. In this article, we will discuss the biology of CDCA3, its potential as a drug target, and its potential as a biomarker for MS.

The Biology of CDCA3

CDCA3 is a member of the cadherin family, which is a group of transmembrane proteins that are involved in cell-cell adhesion. CDCA3 is a 21-kDa protein that is expressed in the CNS, including the brain, spinal cord, and retina. It is involved in the development and maintenance of the blood-brain barrier (BBB), which is a specialized barrier that separates the brain from the surrounding blood vessels and lymphatic system.

CDCA3 functions as a negative regulator of the Wnt signaling pathway, which is a critical pathway for the development and maintenance of neural stem cells. The Wnt signaling pathway is involved in the development and maintenance of the neural stem cells that give rise to the CNS, including neurons and glial cells.

In addition to its role in the Wnt signaling pathway, CDCA3 is also involved in the regulation of cell adhesion, as well as the regulation of the cell cycle. It is a transcription factor that is involved in the regulation of gene expression, and it has has been shown to play a role in the regulation of stem cell proliferation and differentiation.

The potential drug target of CDCA3

CDCA3 has been identified as a potential drug target for MS due to its involvement in the development and maintenance of the BBB. The BBB is a specialized barrier that separates the brain from the surrounding blood vessels and lymphatic system, and it is thought to play a critical role in the regulation of the exchange of nutrients, oxygen, and other substances between the brain and the surrounding body.

Studies have shown that CDCA3 is involved in the regulation of the BBB, and that it plays a role in the development of the BBB in the brain. By targeting CDCA3, researchers have identified a potential mechanism of action for new DMTs.

The potential biomarker of CDCA3

CDCA3 has also been identified as a potential biomarker for MS due to its expression in the CNS. The expression of CDCA3 has been shown to be associated with the development of MS, and researchers have used it as a potential biomarker for the disease.

Studies have shown that the expression of CDCA3 is significantly increased in the brains of people with MS compared to healthy controls. This increase in the expression of CDCA3 has been shown to be associated with the development of MS, and it may be a potential diagnostic biomarker for the disease.

Conclusion

CDCA3 is a protein that is expressed in the CNS and is involved in the development and maintenance of the blood-brain barrier. It has been identified as a potential drug target for MS due to its involvement in the regulation of the BBB and the development of the BBB in the brain. In addition, CDCA3 has also been identified as a potential biomarker for MS due to its expression in the CNS. Further research is needed to

Protein Name: Cell Division Cycle Associated 3

Functions: F-box-like protein which is required for entry into mitosis. Acts by participating in E3 ligase complexes that mediate the ubiquitination and degradation of WEE1 kinase at G2/M phase (By similarity)

The "CDCA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDCA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15